Prashanthi Dharanipragada
Overview
Explore the profile of Prashanthi Dharanipragada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu S, Dharanipragada P, Lomeli S, Wang Y, Zhang X, Yang Z, et al.
Nat Med
. 2023 Apr;
29(5):1123-1134.
PMID: 37106167
Metastasis and failure of present-day therapies represent the most common causes of mortality in patients with cutaneous melanoma. To identify the underlying genetic and transcriptomic landscapes, in this study we...
2.
Dharanipragada P, Parekh N
Cells
. 2023 Feb;
12(4).
PMID: 36831263
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and frequently develops through the accumulation of several genetic variations. With the advancement in high-throughput techniques, in...
3.
Dharanipragada P, Zhang X, Liu S, Lomeli S, Hong A, Wang Y, et al.
Cancer Discov
. 2023 Jan;
13(4):880-909.
PMID: 36700848
Significance: Acquired resistance often results in heterogeneous, redundant survival mechanisms, which challenge strategies aimed at reversing resistance. Acquired-resistant melanomas recurrently evolve resistance-driving and resistance-specific amplicons via ecDNAs and CGRs, thereby...
4.
Hung K, Luebeck J, Dehkordi S, Colon C, Li R, Wong I, et al.
Nat Genet
. 2022 Oct;
54(11):1746-1754.
PMID: 36253572
Extrachromosomal DNA (ecDNA) is a common mode of oncogene amplification but is challenging to analyze. Here, we adapt CRISPR-CATCH, in vitro CRISPR-Cas9 treatment and pulsed field gel electrophoresis of agarose-entrapped...
5.
Dharanipragada P, Parekh N
Precis Clin Med
. 2022 Jun;
2(4):246-258.
PMID: 35693879
Diffuse large B-cell lymphoma (DLBCL) is the aggressive form of haematological malignancies with relapse/refractory in ~ 40% of cases. It mostly develops due to accumulation of various genetic and epigenetic...
6.
Song K, Minami J, Huang A, Dehkordi S, Lomeli S, Luebeck J, et al.
Cancer Discov
. 2021 Dec;
12(4):1046-1069.
PMID: 34930786
Significance: Understanding the structure and dynamics of oncogene amplifications is critical for overcoming tumor relapse. BRAF amplifications are highly plastic under MAPKi dosage challenges in melanoma, through involvement of de...
7.
SeqVItA: Sequence Variant Identification and Annotation Platform for Next Generation Sequencing Data
Dharanipragada P, Seelam S, Parekh N
Front Genet
. 2018 Nov;
9:537.
PMID: 30487811
The current trend in clinical data analysis is to understand how individuals respond to therapies and drug interactions based on their genetic makeup. This has led to a paradigm shift...
8.
Dharanipragada P, Vogeti S, Parekh N
PLoS One
. 2018 Apr;
13(4):e0195334.
PMID: 29621297
Discovery of copy number variations (CNVs), a major category of structural variations, have dramatically changed our understanding of differences between individuals and provide an alternate paradigm for the genetic basis...